AV网站国产不卡|a阿V天堂亚洲阿∨天堂在线|a在线视频播放免费视|yy717午夜福利

<sup id="zd4np"></sup>

array(25) {
  ["id"]=>
  string(5) "79991"
  ["name"]=>
  string(6) "高瑛"
  ["avatar"]=>
  string(47) "https://mip.mfk.com/statics/images/touxiang.png"
  ["status"]=>
  string(1) "0"
  ["rank_type"]=>
  string(2) "37"
  ["duodian_main_id"]=>
  string(1) "0"
  ["miaopai"]=>
  string(0) ""
  ["graphic_consult"]=>
  string(1) "0"
  ["position"]=>
  string(12) "副研究員"
  ["introduction"]=>
  string(4852) "招生專業(yè)：分子醫(yī)學(xué)
Email:?gaoying@sysucc.org.cn
個(gè)人簡(jiǎn)介：2020年博士畢業(yè)后在本中心做博士后，2024年轉(zhuǎn)聘副研究員。主要研究方向?yàn)榧?xì)胞自噬、囊泡運(yùn)輸或細(xì)胞外囊泡生物形成的新機(jī)制及對(duì)腫瘤發(fā)生發(fā)展的作用，尋找新的腫瘤生物標(biāo)志物和潛在靶點(diǎn)。目前以第一作者/通訊作者（含共同）在Cell Res（兩篇），Signal Transduct Target Ther，J Extracell Vesicles，Cell Death Differ，Cell Death Dis（兩篇），Cancer lett 等國(guó)際主流學(xué)術(shù)期刊發(fā)表SCI論文多篇，獲得發(fā)明專利1項(xiàng)；廣東省細(xì)胞生物學(xué)會(huì)理事，主持國(guó)家自然科學(xué)基金青年項(xiàng)目和面上項(xiàng)目、中國(guó)博士后創(chuàng)新人才支持計(jì)劃等科研項(xiàng)目，作為團(tuán)隊(duì)負(fù)責(zé)人榮獲第一屆全國(guó)博士后創(chuàng)新創(chuàng)業(yè)大賽揭榜領(lǐng)題賽優(yōu)勝獎(jiǎng)。
教育背景：
2017/09-2020/07，中山大學(xué)，腫瘤防治中心，博士
2013/09-2016/07，中山大學(xué)，藥學(xué)院，碩士
2009/09-2013/07，中國(guó)藥科大學(xué)，學(xué)士
代表性論文：
(1)Xiaodan Huang#, Lanqing Huo#, Beibei Xiao#, Yi Ouyang#, Foping Chen, Junyun Li, Xueping Zheng, Denghui Wei, Yuanzhong Wu, Ruhua Zhang, Xinping Cao*, Tiebang Kang* and Ying Gao*.?Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer.?Cell Death Differ, 2024 Jan;31(1):78-89. (IF: 13.7)
(2)Linxia Qian#, Zhonghan Zhang#, Ruhua Zhang#, Xueping Zheng, Beibei Xiao, Xiaomin Zhang, Yuanzhong Wu, Yang Chen, Xingding Zhang, Penghui Zhou, Qingling Fu*, Tiebang Kang*, Ying Gao*.?Activated STING-containing R-EVs from iPSC-derived MSCs promote antitumor immunity. Cancer Lett, 2024 Jun 22:597:217081. (IF: 9.1)
(3)?Lanqing Huo#, Xiaodan Huang#, Ying Wang#, Yi Ouyang#, Xueping Zheng, Yingyi Ouyang, Xinping Cao, Kai Chen, Denghui Wei, Yuanzhong Wu, Ruhua Zhang, Yujie Lin*, Tiebang Kang*, Ying Gao*.?RAB33A Promotes Metastasis via RhoC Accumulation through Non-canonical Autophagy in Cervical Cancer.?Cell Death Dis, 2025?Feb, 17(accepted).?(IF: 8.1)
(4)Yujie Lin#, Denghui Wei#, Xiaobo He#, Lanqing Huo#, Jingxuan Wang, Xia Zhang, Yuanzhong Wu, Ruhua Zhang, Ying Gao*,?Tiebang Kang*.?RAB22A sorts epithelial growth factor receptor (EGFR) from early endosomes to recycling endosomes for microvesicles release.?J Extracell Vesicles, 2024?Jul;13(7):e12494.?(IF: 15.5)
(5)Ying Gao#, Xueping Zheng#, Boyang Chang#, Yujie Lin#, Xiaodan Huang#, Wen Wang#, Shirong Ding, Weixiang Zhan, Shang Wang, Beibei Xiao, Lanqing Huo, Youhui Yu, Yilin Chen, Run Gong, Yuanzhong Wu, Ruhua Zhang, Li Zhong, Xin Wang, Qiuyan Chen, Song Gao, Zhengfan Jiang, Denghui Wei*, Tiebang Kang*. Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. Cell Res, 2022 Dec; 32(12): 1086-1104. (IF: 28.1,?Cell Research top articles from the past 3 years)
Research Highlight by Li Yu*.?A new route for EV biogenesis. Cell Res, 2023 Feb; 33(2): 87-88.?(IF: 28.1)
Commentary and Views?by Yaping Han, Jianfei Zheng, Liang Ge*.?Activated STING1 rides the Rafeesome. Autophagy, 2023 Aug 6:1-4. (IF: 14.6) 
(6)Denghui Wei#, Weixiang Zhan#, Ying Gao#, Liyan Huang, Run Gong, Wen Wang, Ruhua Zhang, Yuanzhong Wu, Song Gao, Tiebang Kang*. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res, 2021 Feb;31(2):157-177. (IF: 28.1)
Research Highlight?by Candia M. Kenific, Haiying Zhang*,?David Lyden*.?An exosome pathway without an ESCRT. Cell Res, 2021 Feb;31(2):105-106. (IF: 28.1)
(7)Weixiang Zhan#, Yina Liu#,?Ying Gao#, Run Gong, Wen Wang, Ruhua Zhang, Yuanzhong Wu, TiebangKang, Denghui Wei*.?RMI2 plays crucial roles in growth and metastasis of lung cancer. ?Signal Transduct Target Ther, 2020 Sep, 5(1): 188.?(IF: 40.8)
(8)Ying Gao#, Yajun Liu#, Liang Hong, Zuolong Yang, Xinran Cai, Xiaoyun Chen, Yuanyuan Fu, Yujie Lin, Weijie Wen, Sitong Li, Xingguo Liu, Heqing Huang, Andreas Vogt, Peiqing Liu*, Xiao-Ming Yin*, Min Li*. Golgi-associated LC3 lipidation requires V-ATPase innoncanonical autophagy. ?Cell Death Dis, 2016 Aug, 7(8): e2330.?(IF: 8.1)
主持的基金：
(1) 國(guó)家自然科學(xué)基金委員會(huì)，面上項(xiàng)目，32370835，新型細(xì)胞器Rafeesome介導(dǎo)p62分泌促進(jìn)肝癌發(fā)生發(fā)展的作用及其機(jī)制，2024-01-01至2027-12-31，50萬(wàn)元，在研，主持
(2) 國(guó)家自然科學(xué)基金委員會(huì)，青年科學(xué)基金項(xiàng)目，32100544，自噬外泌體的鑒定及形成機(jī)制研究，2022-01-01至2023-12-31，20萬(wàn)元，在研，主持
(3) 中國(guó)博士后基金委，中國(guó)博士后創(chuàng)新人才支持計(jì)劃，BX2021394，細(xì)胞外囊泡的STING在腫瘤微環(huán)境中的功能及形成機(jī)制，2021-07至2023-06，63萬(wàn)元，結(jié)題，主持
專利：
一種包含激活型干擾素基因刺激蛋白的納米顆粒及其制備方法和應(yīng)用，ZL202211213710.3，2023-05-30授權(quán)"
  ["adept"]=>
  string(156) "長(zhǎng)期從事腫瘤細(xì)胞生物學(xué)研究，聚焦于胞內(nèi)囊泡運(yùn)輸以及胞外囊泡分泌的調(diào)控與干預(yù)在腫瘤微環(huán)境中的作用和機(jī)制研究"
  ["duodian_doctor_id"]=>
  string(6) "115310"
  ["source_from"]=>
  string(12) "醫(yī)院官網(wǎng)"
  ["is_jingxuan"]=>
  string(1) "0"
  ["title_num"]=>
  string(0) ""
  ["created"]=>
  string(10) "1754967873"
  ["doctor_title"]=>
  string(12) "副研究員"
  ["is_seniority"]=>
  int(1)
  ["province_id"]=>
  int(0)
  ["city_id"]=>
  int(0)
  ["hospital_sort"]=>
  string(2) "32"
  ["hospital"]=>
  array(1) {
    [0]=>
    array(29) {
      ["id"]=>
      string(5) "19763"
      ["name"]=>
      string(30) "中山大學(xué)腫瘤防治中心"
      ["grade_id"]=>
      string(1) "2"
      ["grade"]=>
      string(0) ""
      ["type"]=>
      string(1) "1"
      ["duodian_hospital_id"]=>
      string(3) "814"
      ["address"]=>
      string(27) "廣州市東風(fēng)東路651號(hào)"
      ["is_gongli"]=>
      string(1) "1"
      ["logo"]=>
      string(72) "http://pic.39yst.com/group2/M00/8B/F7/Co2PPWKfAdKACBy1AABiOqd-PC074.jpeg"
      ["is_pay"]=>
      string(1) "0"
      ["pic"]=>
      string(72) "http://pic.39yst.com/group2/M00/99/67/Co2PPWZ-H3qABl2PAAK_8SuU6HY43.jpeg"
      ["is_top100"]=>
      string(1) "1"
      ["parent_areaid"]=>
      string(2) "19"
      ["areaid"]=>
      string(4) "1601"
      ["top100_sort"]=>
      string(2) "32"
      ["guide"]=>
      string(0) ""
      ["tel"]=>
      string(38) "020-87673713，020-87765368           "
      ["is_seniority"]=>
      string(1) "1"
      ["hospital_title"]=>
      string(6) "三甲"
      ["hospital_grade_id"]=>
      string(1) "2"
      ["hospital_type"]=>
      string(12) "綜合醫(yī)院"
      ["hospital_type_id"]=>
      string(1) "1"
      ["hospital"]=>
      string(30) "中山大學(xué)腫瘤防治中心"
      ["department_id"]=>
      string(1) "0"
      ["duodian_department_id"]=>
      string(6) "213417"
      ["duodian_department_pid"]=>
      string(6) "213396"
      ["department_name"]=>
      string(0) ""
      ["hospital_department"]=>
      string(12) "臨床專家"
      ["duty"]=>
      array(0) {
      }
    }
  }
  ["version"]=>
  int(41)
  ["isHaveSource"]=>
  int(0)
  ["duty"]=>
  string(0) ""
}